Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients.
Title | Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. |
Publication Type | Journal Article |
Year of Publication | 2006 |
Authors | Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, Irwin MR, Motivala SJ, Furst DE |
Journal | Qual Life Res |
Volume | 15 |
Issue | 8 |
Pagination | 1383-94 |
Date Published | 2006 Oct |
ISSN | 0962-9343 |
Keywords | Activities of Daily Living, Arthritis, Rheumatoid, Female, Humans, Male, Multicenter Studies as Topic, Psychometrics, Randomized Controlled Trials as Topic, Scleroderma, Systemic, Sickness Impact Profile, Surveys and Questionnaires, United States |
Abstract | OBJECTIVE: Structural validity for the Health Assessment Questionnaire-Disability Index (HAQ-DI) has recently been provided for patients with rheumatoid arthritis (RA). The goal of the current study was to examine the structural validity of the HAQ-DI in patients with systemic sclerosis (SSc, scleroderma) and to compare its performance with that in patients with RA. METHODS: The HAQ-DI structural validity was first assessed in a sample of 100 scleroderma patients using confirmatory factor analysis. Second, the similarity of factor structures between SSc patients (n = 291) and RA patients (n = 278) was tested using a multigroup structural validity model to assure that comparison of scores between these two diagnostic groups is appropriate. RESULTS: Results yielded a single-factor HAQ-DI score which favored the current scoring system of the HAQ-DI (model fit was CFI = 0.99 and RMSEA = 0.04). Moreover, even the most stringent model of multigroup structural validity affirmed the similarity between SSc and RA patients on the HAQ-DI (model fit was CFI = 0.99 and RMSEA = 0.04) nor was it different from a model without any demands on group similarity: CFI difference = 0.007; chi(2) = 4.29, df = 26, p=0.99. CONCLUSION: The current results indicate that a single-factor HAQ-DI is appropriate for future clinical trials in scleroderma and, in addition, HAQ-DI scores among patients with SSc and early RA can be compared legitimately with one another. |
DOI | 10.1007/s11136-006-0018-8 |
Alternate Journal | Qual Life Res |
PubMed ID | 16826439 |
Grant List | U01 HL60587 / HL / NHLBI NIH HHS / United States |